{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:58Z","timestamp":1791041878752,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1124\/dmd.121.000742","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:40:12Z","timestamp":1656596412000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes"],"prefix":"10.1016","volume":"51","author":[{"given":"Hiroshi","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000742_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/mnfr.200900281","article-title":"Toxicology and risk assessment of coumarin: focus on human data","volume":"54","author":"Abraham","year":"2010","journal-title":"Mol Nutr Food Res"},{"key":"10.1124\/dmd.121.000742_bib2","first-page":"1964","article-title":"Thalidomide metabolism by the CYP2C subfamily","volume":"8","author":"Ando","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.121.000742_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejps.2015.03.015","article-title":"Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450","volume":"73","author":"Boji\u0107","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.121.000742_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2005.02483.x","article-title":"Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant","volume":"60","author":"Brown","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15284-1","article-title":"Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450","volume":"27","author":"Busby","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib6","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1517\/13543784.7.12.2043","article-title":"Thalidomide revisited: pharmacology and clinical applications","volume":"7","author":"Calabrese","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.121.000742_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1517\/17425250802522188","article-title":"Role of flavin-containing monooxygenase in drug development","volume":"4","author":"Cashman","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.121.000742_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.pharmtox.46.120604.141043","article-title":"Human flavin-containing monooxygenases","volume":"46","author":"Cashman","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.121.000742_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bcp.2011.11.029","article-title":"In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3","volume":"83","author":"Catucci","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/tx900367p","article-title":"Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate","volume":"23","author":"Chowdhury","year":"2010","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/tx4004215","article-title":"Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide","volume":"27","author":"Chowdhury","year":"2014","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/carcin\/bgh258","article-title":"Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers","volume":"25","author":"Fujieda","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.121.000742_bib14","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1073\/pnas.78.4.2545","article-title":"Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite","volume":"78","author":"Gordon","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.121.000742_bib15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/ATVBAHA.114.303252","article-title":"Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine","volume":"34","author":"Hartiala","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/dmd.121.000742_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/jpet.300.1.298","article-title":"Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes","volume":"300","author":"Hashizume","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000742_bib17","first-page":"207","article-title":"Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities","volume":"26","author":"Hickman","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/bmc.466","article-title":"Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography","volume":"19","author":"Huang","year":"2005","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.121.000742_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3565(25)27556-5","article-title":"Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) in man","volume":"155","author":"Hucker","year":"1967","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000742_bib20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(70)90241-2","article-title":"Trimethylaminuria: the fish-odour syndrome","volume":"2","author":"Humbert","year":"1970","journal-title":"Lancet"},{"key":"10.1124\/dmd.121.000742_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/dmd.108.023358","article-title":"Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+\/\u2212)-suprofen: a comparison of kinetics and probe substrate selection","volume":"37","author":"Hutzler","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2468-1253(21)00018-2","article-title":"Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial","volume":"6","author":"Ishikawa","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/dmd.121.000742_bib23","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1136\/gutjnl-2013-305827","article-title":"The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial","volume":"63","author":"Ishikawa","year":"2014","journal-title":"Gut"},{"key":"10.1124\/dmd.121.000742_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.121.000742_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1124\/dmd.121.000742_bib26","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0021-9258(17)35823-4","article-title":"Reactions of the 4a-hydroperoxide of liver microsomal flavin-containing monooxygenase with nucleophilic and electrophilic substrates","volume":"261","author":"Jones","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000742_bib27","doi-asserted-by":"crossref","first-page":"21419","DOI":"10.1038\/srep21419","article-title":"Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model","volume":"6","author":"Kazuki","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.121.000742_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: the tragedy of birth defects and the effective treatment of disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14737140.2015.1033407","article-title":"Lenalidomide in multiple myeloma","volume":"15","author":"Kim","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1124\/dmd.121.000742_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00008571-200311000-00005","article-title":"Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)","volume":"13","author":"Kiyotani","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.121.000742_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/00498254.2014.979271","article-title":"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-\/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation","volume":"45","author":"Koyanagi","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pharmthera.2005.01.001","article-title":"Mammalian flavin-containing monooxygenases: structure\/function, genetic polymorphisms and role in drug metabolism","volume":"106","author":"Krueger","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.121.000742_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2131\/jts.46.553","article-title":"Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5\u2032-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species","volume":"46","author":"Kuwagata","year":"2021","journal-title":"J Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0278-6915(99)00010-1","article-title":"Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment","volume":"37","author":"Lake","year":"1999","journal-title":"Food Chem Toxicol"},{"key":"10.1124\/dmd.121.000742_bib35","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1124\/dmd.121.000742_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1124\/jpet.104.067793","article-title":"Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans","volume":"310","author":"Lu","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000742_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0003-9861(71)90048-8","article-title":"The distinct nature and function of NADPH-cytochrome c reductase and the NADPH-dependent mixed-function amine oxidase of porcine liver microsomes","volume":"145","author":"Masters","year":"1971","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.121.000742_bib38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2131\/jts.46.525","article-title":"Roles of human cytochrome P450 1A2 in coumarin 3,4-epoxidation mediated by untreated hepatocytes and by those metabolically inactivated with furafylline in previously transplanted chimeric mice","volume":"46","author":"Miura","year":"2021","journal-title":"J Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/acs.chemrestox.9b00446","article-title":"Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4\u2032- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice","volume":"33","author":"Miura","year":"2020","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2131\/jts.46.311","article-title":"Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes","volume":"46","author":"Miura","year":"2021","journal-title":"J Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-7992(85)90015-6","article-title":"Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella","volume":"142","author":"Mori","year":"1985","journal-title":"Mutat Res"},{"key":"10.1124\/dmd.121.000742_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2131\/jts.42.343","article-title":"Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity","volume":"42","author":"Murayama","year":"2017","journal-title":"J Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2131\/jts.43.369","article-title":"Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA","volume":"43","author":"Murayama","year":"2018","journal-title":"J Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1021\/tx4004374","article-title":"Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor","volume":"27","author":"Murayama","year":"2014","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/bdd.2115","article-title":"Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies","volume":"39","author":"Murayama","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.121.000742_bib46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2131\/jts.46.371","article-title":"Metabolic activation and deactivation of dietary-derived coumarin mediated by cytochrome P450 enzymes in rat and human liver preparations","volume":"46","author":"Murayama","year":"2021","journal-title":"J Toxicol Sci"},{"key":"10.1124\/dmd.121.000742_bib47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2133\/dmpk.24.218","article-title":"Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors","volume":"24","author":"Nagashima","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/00498254.2013.816891","article-title":"Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans","volume":"44","author":"Nakamaru","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2133\/dmpk.DMPK-12-RV-089","article-title":"Clinical evidence of pharmacokinetic changes in thalidomide therapy","volume":"28","author":"Nakamura","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib51","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1021\/acs.chemrestox.5b00381","article-title":"Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice","volume":"28","author":"Nishiyama","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.dmpk.2019.08.005","article-title":"Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6","volume":"35","author":"Notsu","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.121.000776","article-title":"Linezolid Metabolism is Catalyzed by CYP2J2, CYP4F2 and CYP1B1","volume":"50","author":"Obach","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/dmd.108.024679","article-title":"Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5","volume":"37","author":"Okada","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib55","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0021-9258(18)60338-2","article-title":"A new cytochrome in liver microsomes","volume":"237","author":"Omura","year":"1962","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000742_bib56","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/bdd.2209","article-title":"Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling","volume":"40","author":"Ota","year":"2019","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.121.000742_bib57","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1124\/dmd.121.000742_bib58","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/molpharm.120.000042","article-title":"Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism","volume":"98","author":"Parikh","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/00498254.2017.1422156","article-title":"Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes\u2122 model","volume":"49","author":"Parmentier","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/00498254.2019.1643515","article-title":"Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease","volume":"50","author":"Phillips","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib61","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1016\/S0021-9258(18)50388-4","article-title":"The liver microsomal FAD-containing monooxygenase. Spectral characterization and kinetic studies","volume":"254","author":"Poulsen","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000742_bib62","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.1021\/bi973011m","article-title":"Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate","volume":"37","author":"Racha","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.121.000742_bib63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/138920010791110917","article-title":"Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters","volume":"11","author":"Rendic","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000742_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/tx500444e","article-title":"Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals","volume":"28","author":"Rendic","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib65","article-title":"Non-P450 enzymes catalyzing oxidation-reduction of endogenous compounds and xenobiotics: Flavin-containing monooxygenase (FMO), monoamine oxidase (MAO), aldehyde oxidase (AO), and NADPH-quinone oxidoreductase (NQO)","author":"Rendic","year":"2022","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.121.000742_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mnfr.200900211","article-title":"In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment","volume":"54","author":"Rietjens","year":"2010","journal-title":"Mol Nutr Food Res"},{"key":"10.1124\/dmd.121.000742_bib67","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1208\/s12248-012-9401-2","article-title":"Pharmacokinetics and tissue disposition of lenalidomide in mice","volume":"14","author":"Rozewski","year":"2012","journal-title":"AAPS J"},{"key":"10.1124\/dmd.121.000742_bib68","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/ejhg.2011.214","article-title":"Clinical utility gene card for: trimethylaminuria","volume":"20","author":"Shephard","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"10.1124\/dmd.121.000742_bib69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002040050403","article-title":"Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans","volume":"71","author":"Shimada","year":"1997","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.121.000742_bib70","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/acs.chemrestox.6b00083","article-title":"Structure-function studies of naphthalene, phenanthrene, biphenyl, and their derivatives in interaction with and oxidation by cytochromes P450 2A13 and 2A6","volume":"29","author":"Shimada","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib71","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000742_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100936","article-title":"Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing","volume":"9","author":"Shimizu","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/dmd.121.000742_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100420","article-title":"A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects","volume":"41","author":"Shimizu","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib74","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/00498254.2016.1247218","article-title":"Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice","volume":"47","author":"Shimizu","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.11.004","article-title":"In vivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice","volume":"37","author":"Shimizu","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dmpk.2020.07.001","article-title":"Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3)","volume":"35","author":"Shimizu","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.dmpk.2019.06.001","article-title":"Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database","volume":"34","author":"Shimizu","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib78","first-page":"208","article-title":"Predicted Contributions of Flavin-Containing Monooxygenases to the N-oxygenation of Drug Candidates Based on Their Estimated Base Dissociation Constants","volume":"22","author":"Taniguchi-Takizawa","year":"2021","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000742_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.dmpk.2014.09.006","article-title":"Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans","volume":"30","author":"Taniguchi-Takizawa","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P","article-title":"Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen\u2019s disease patients","volume":"14","author":"Teo","year":"2000","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.121.000742_bib81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/00498254.2017.1353716","article-title":"Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19","volume":"48","author":"Toda","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib82","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0009-9236(98)90050-9","article-title":"Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone","volume":"64","author":"Trapnell","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000742_bib83","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2125.2009.03548.x","article-title":"Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A","volume":"68","author":"Turpault","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib84","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1124\/jpet.111.185009","article-title":"Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys","volume":"339","author":"Uehara","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000742_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100410","article-title":"An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals","volume":"42","author":"Uehara","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000742_bib86","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/dmd.117.075184","article-title":"Marmoset Flavin-Containing Monooxygenase 3 in the Liver Is a Major Benzydamine and Sulindac Sulfide Oxygenase","volume":"45","author":"Uehara","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib87","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/00498254.2015.1096980","article-title":"Caffeine 7-N-demethylation and C-8-oxidation mediated by liver microsomal cytochrome P450 enzymes in common marmosets","volume":"46","author":"Uehara","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113721","article-title":"The marmoset cytochrome P450 superfamily: Sequence\/phylogenetic analyses, genomic structure, and catalytic function","volume":"171","author":"Uehara","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib54295276","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115125","article-title":"Molecular and functional characterization of flavin-containing monooxygenases in pigs, dogs, and cats","volume":"202","author":"Uno","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib89","article-title":"A Comprehensive Investigation of Dog Cytochromes P450 3A (CYP3A) Reveals A Functional Role of Newly Identified CYP3A98 in Small Intestine","author":"Uno","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib90","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.122.000930","article-title":"Cytochrome P450 2J (CYP2J) Genes in Dogs, Cats, and Pigs Are Expressed and Encode Functional Drug-Metabolizing Enzymes","author":"Uno","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.06.008","article-title":"Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes","volume":"121","author":"Uno","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib92","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bcp.2017.12.015","article-title":"Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans","volume":"153","author":"Uno","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114887","article-title":"Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans","volume":"197","author":"Uno","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib94","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3109\/00498254.2016.1147102","article-title":"Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling","volume":"46","author":"Utoh","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000742_bib95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1570-0232(03)00473-2","article-title":"Liquid chromatographic determination of the glutathione conjugate and ring-opened metabolites formed from coumarin epoxidation","volume":"794","author":"Vassallo","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.121.000742_bib96","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","article-title":"Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018","volume":"29","author":"Warren","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.121.000742_bib97","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1055-9965.EPI-05-0782","article-title":"Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men","volume":"15","author":"Wu","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/dmd.121.000742_bib98","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0090-9556(24)15179-3","article-title":"Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes","volume":"28","author":"Wynalda","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000742_bib99","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/carcin\/13.10.1789","article-title":"Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes","volume":"13","author":"Yamazaki","year":"1992","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.121.000742_bib100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0006-2952(98)00133-6","article-title":"Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes","volume":"56","author":"Yamazaki","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib101","doi-asserted-by":"crossref","first-page":"27438","DOI":"10.1074\/jbc.271.44.27438","article-title":"Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4\/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5.","volume":"271","author":"Yamazaki","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000742_bib102","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/0006-2952(94)90579-7","article-title":"Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7 alpha- and coumarin 7-hydroxylations","volume":"48","author":"Yamazaki","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib103","doi-asserted-by":"crossref","first-page":"30885","DOI":"10.1074\/jbc.M105011200","article-title":"Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase","volume":"276","author":"Yamazaki","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000742_bib104","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/138920007780866825","article-title":"Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients","volume":"8","author":"Yamazaki","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000742_bib105","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.bcp.2013.03.020","article-title":"Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities","volume":"85","author":"Yamazaki","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib106","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40780-021-00209-8","article-title":"Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments","volume":"7","author":"Yamazaki","year":"2021","journal-title":"J Pharm Health Care Sci"},{"key":"10.1124\/dmd.121.000742_bib107","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/tx200005g","article-title":"In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice","volume":"24","author":"Yamazaki","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib108","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1021\/acs.chemrestox.6b00210","article-title":"Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis\/Accelerator Mass Spectrometry","volume":"29","author":"Yamazaki","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib109","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1021\/acs.chemrestox.6b00136","article-title":"Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology","volume":"29","author":"Yamazaki","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/tx400008g","article-title":"In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice","volume":"26","author":"Yamazaki","year":"2013","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib111","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/tx300009j","article-title":"In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice","volume":"25","author":"Yamazaki","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000742_bib112","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1021\/bi00026a020","article-title":"Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates","volume":"34","author":"Yamazaki","year":"1995","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.121.000742_bib113","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2007.03070.x","article-title":"Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction","volume":"65","author":"Youdim","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib114","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bcp.2014.04.019","article-title":"Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs","volume":"90","author":"Yamazaki","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000742_bib115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1317084110","article-title":"Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans","volume":"110","author":"Zeldis","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.121.000742_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03602538809049617","article-title":"Flavin-containing monooxygenases: catalytic mechanism and substrate specificities","volume":"19","author":"Ziegler","year":"1988","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.121.000742_bib117","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1081\/DMR-120005650","article-title":"An overview of the mechanism, substrate specificities, and structure of FMOs","volume":"34","author":"Ziegler","year":"2002","journal-title":"Drug Metab Rev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562400905X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562400905X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:58:20Z","timestamp":1739955500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562400905X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S009095562400905X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000742","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}